A Nationwide Cohort Study of Delta and Omicron SARS-CoV-2 Outcomes in Vaccinated Individuals With Chronic Lung Disease
CHEST Journal,
Год журнала:
2024,
Номер
166(4), С. 685 - 696
Опубликована: Июнь 11, 2024
Язык: Английский
Outcomes of SARS‐CoV‐2 Omicron infection in vaccinated children with asthma versus matched controls: A nationwide population‐based study
Pediatric Pulmonology,
Год журнала:
2024,
Номер
59(5), С. 1498 - 1501
Опубликована: Янв. 30, 2024
Please
note:
The
publisher
is
not
responsible
for
the
content
or
functionality
of
any
supporting
information
supplied
by
authors.
Any
queries
(other
than
missing
content)
should
be
directed
to
corresponding
author
article.
Язык: Английский
Recent insights into the impacts of COVID-19 on pediatric asthma
Expert Review of Clinical Immunology,
Год журнала:
2024,
Номер
20(11), С. 1347 - 1366
Опубликована: Авг. 13, 2024
Introduction
The
emergence
of
Severe
Acute
Respiratory
Syndrome
Coronavirus
2
(SARS-CoV-2)
and
the
subsequent
coronavirus
disease
2019
(COVID-19)
pandemic
has
raised
questions
about
its
impact
on
pediatric
asthma.
This
review
analyzes
latest
research
to
offer
a
comprehensive
understanding
dynamics
between
COVID-19
Язык: Английский
COVID-19 severity and risk of SARS-CoV-2-associated asthma exacerbation by time since booster vaccination: a longitudinal analysis of data from the COVIDENCE UK study
medRxiv (Cold Spring Harbor Laboratory),
Год журнала:
2024,
Номер
unknown
Опубликована: Июнь 30, 2024
Abstract
Background
In
several
countries,
COVID-19
booster
vaccinations
are
offered
annually
to
priority
groups,
but
many
people
have
not
been
vaccinated
in
over
a
year.
We
aimed
assess
the
association
between
time
since
vaccination
and
characteristics
of
breakthrough
infection.
also
assessed
whether
incident
continued
associate
with
asthma
exacerbations
boosted
individuals,
risk
COVID-19-associated
exacerbation
was
affected
by
vaccination.
Methods
COVIDENCE
UK
is
prospective,
longitudinal,
population-based
study
COVID-19.
included
adult
participants
who
had
received
≥1
Time
binarised
at
6
months
or
12
according
vaccine
eligibility
subgroup.
used
logistic,
Cox,
linear
regression
obtain
adjusted
estimates
for
infection
severity,
symptom
duration,
acute
changes
health-related
quality
life
(measured
EQ-5D-3L
Index).
then
using
multilevel
mixed
models,
Results
7391
reported
Across
all
subgroups,
greater
associated
increased
odds
requiring
bedrest
(
vs
milder
symptoms),
highest
adults
aged
65–75
years
(1.83
[95%
CI
1.51–2.23]
when
>6
≤6
prior).
However,
we
observed
little
evidence
duration.
Vaccination
>12
prior
≤12
months)
small
decrease
Index
among
younger
than
65
(-0.03
points
[-0.04
-0.01]).
Among
2100
asthma,
exacerbation,
both
after
(OR
5.31
[4.36–6.48])
later
(6.06
[3.23–11.38]),
difference
point
specifically
considering
severe
(6.82
[4.88–9.54]
10.06
[3.90–25.92]
months).
Conclusion
Longer
consistently
associates
more
infections,
may
potentially
increase
exacerbations.
These
findings
highlight
importance
ensuring
those
currently
eligible
receive
their
vaccinations,
need
research
on
further
no
longer
boosters.
Язык: Английский
Influence of Bronchopulmonary Diseases on the Course and Outcome of COVID-19: a Literature Review
Juvenis scientia,
Год журнала:
2024,
Номер
10(4), С. 19 - 28
Опубликована: Авг. 30, 2024
The
SARS-CoV‑2
coronavirus
has
become
a
major
global
health
concern.
Infection
with
caused
millions
of
deaths
worldwide,
and
the
case
fatality
rate
been
found
to
be
largely
related
pre-existing
clinical
conditions.
main
manifestation
COVID‑19
is
presence
respiratory
symptoms.
Severe
complications
are
most
often
observed
in
people
significant
medical
histories.
virus
primarily
attacks
system,
causing
pneumonia
acute
distress
syndrome,
which
can
lead
severe
systemic
inflammation,
multiple
organ
dysfunction,
death,
especially
patients
comorbidities.
A
number
meta-analyses
strongly
suggest
that
comorbid
diseases,
including
chronic
obstructive
pulmonary
disease
interstitial
lung
factors
development
forms
COVID‑19,
worsening
patient
outcomes
survival
rates.
Studies
have
shown
an
association
between
adverse
expression
level
angiotensin-converting
enzyme
2
(ACE2)
these
patients.
Regarding
other
system
pathologies,
such
as
bronchial
asthma
cystic
fibrosis,
it
known
unfavorable
factor
long-term
immunosuppressive
pharmacotherapy
preceding
infection.
In
this
article,
we
highlight
comorbidities
better
understand
pathogenesis
COVID‑19.
Язык: Английский